Profile of patients undergoing third line anti-retroviral therapy

Autor:	T. Jeetenkumar Singh, H. Rebachandra Singh, P Dhileeban Maharajan, L Janani, S. Bhagyabati Devi, Dipul Rudra Paul
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry Human immunodeficiency virus (HIV) Raltegravir medicine.disease_cause Third line Internal medicine medicine Ritonavir Adverse effect Prospective cohort study business Viral load Darunavir medicine.drug
Zdroj:	International Journal of Advances in Medicine. 7:1394
ISSN:	2349-3933 2349-3925
Popis:	Background: India has the third largest human HIV epidemic in the world. The advent of antiretroviral drug began a revolution in the management of HIV. Recent studies have shown that an increasing number of patients experiencing virologic failure on second line Antiretroviral therapy and require third line ART.Methods: This prospective cohort study was conducted in Regional Institute of Medical Sciences, Imphal for a period of two years, to study the clinical, immunological, and virological profile of patients undergoing third line Antiretroviral therapy and to study the early immuno-virological response to third line Antiretroviral therapy.Results: Mean CD4 count before third line ART initiation was 95.90±111.85 cells/μl with 60% of them had CD4 count 100000 copies/ml. After one year of third line ART, 80 % of the patients showed viral suppression (VL
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::90fec2cb8b836e5a2ee90ae36bee0332 https://doi.org/10.18203/2349-3933.ijam20203605 Zobrazit plný text záznamu